Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

NCT05922904

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

NCT02514083

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, Not Recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03192397

Conditions: Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Anemia, +45 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Active, Not Recruiting

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

The Alkmaar MLPTI Cohort Study: Outcomes at 9 Years

NCT05990582

Conditions: Communication Disorders, Developmental Delay, Female Urogenital Diseases and Pregnancy Complications, +25 more
Locations: Noordwest Ziekenhuisgroep Alkmaar, Netherlands

View Trial Details

Active, Not Recruiting

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT05675449

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations: University of Arkansas for Medical Sciences Little Rock, Arkansas, United States

Beverly Hills Cancer Center Beverly Hills, California, United States

Clinical Research Advisors (Encino Satellite Location) Encino, California, United States

Clinical Research Advisors (Korea Town Satellite Location) Los Angeles, California, United States

View all 36 locations

View Trial Details

Active, Not Recruiting

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

NCT06062537

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: CHU Amiens Picardie Amiens, France

CH d'ANNECY Annecy, France

Centre hospitalier d'Argenteuil Argenteuil, France

Hopital de la cote Basque Bayonne, France

View all 31 locations

View Trial Details

Active, Not Recruiting

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

NCT01589302

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations: Ohio State University Medical Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations: Alaska Oncology and Hematology LLC Anchorage, Alaska, United States

Banner MD Anderson Cancer Center Gilbert, Arizona, United States

Alta Bates Comprehensive Cancer Center Berkeley, California, United States

MemorialCare Long Beach Medical Center Long Beach, California, United States

View all 211 locations

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions